Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
暂无分享,去创建一个
L. Rybicki | M. Kalaycio | B. Pohlman | E. Copelan | R. Sobecks | S. Andresen | R. Dean | B. Bolwell | H. Duong | M. Yurch
[1] G. Phillips,et al. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia , 2010, British journal of haematology.
[2] L. Rybicki,et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non‐Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide , 2010, British journal of haematology.
[3] L. Nguyen,et al. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients , 2009, European Journal of Clinical Pharmacology.
[4] L. Rybicki,et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation , 2004, Bone Marrow Transplantation.
[5] J. Radich,et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. , 2003, Blood.
[6] J. Niland,et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] H. Deeg,et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. , 2002, Blood.
[8] J. Wingard,et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] F. Spijkervet,et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Labopin,et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia , 1996, British journal of haematology.
[11] J. Klein,et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. , 1991, Blood.
[12] L. Grochow,et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. , 1987, Cancer research.
[13] R. Brookmeyer,et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.
[14] P. Neiman,et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.
[15] L. Nguyen,et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study , 2005, Cancer Chemotherapy and Pharmacology.
[16] L. Grochow,et al. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics , 1998 .